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Abstract: The incidence and mortality of pancreas cancer converge. There has been little 
advancement in the treatment of pancreas cancer since the acceptance of gemcitabine as 
the standard therapy. Unfortunately, the efficacy of gemcitabine is dismal. While there is 
much discussion  for the development of biomarkers to help direct therapy  in this area, 
there  is  little  action  to  move  them  into  clinical  practice.  Herein,  we  review  potential 
pancreatic cancer biomarkers and discuss the limitations in their implementation. 
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1. Introduction  
Adenocarcinoma of the pancreas is one of the most devastating cancers. More than 44,000 patients 
in the United States will be diagnosed with pancreas cancer in 2011 and almost 38,000 will die in the 
same year [1]. With the yearly incidence rate almost equaling the yearly mortality rate, the diagnosis of 
pancreas cancer is almost always fatal. Adenocarcinoma of the pancreas is clinically divided into three 
subgroups  at  diagnosis:  resectable  (~10–20%),  locally  advanced  unresectable  (~30–40%),  and 
OPEN ACCESS Int. J. Mol. Sci. 2011, 12                       
 
 
5896
metastatic  (~50%).  The  only  chance  of  a  cure  is  with  complete  surgical  resection,  however  the 
understood cure rate in that patient population is still only 5%. On average, patients with resectable, 
locally  advanced  unresectable,  and  metastatic  pancreas  cancer  survive  23,  6–12,  and  ~6  months, 
respectively  [2,3].  Despite  hundreds  of  pre-clinical  and  clinical  trials,  there  are  still  only  limited 
treatment options for pancreatic cancer patients. The adjuvant treatment of pancreatic adenocarcinoma 
is limited to the use of either 5-fluorouracil (5FU) or gemcitabine. These have been proven to have 
equal efficacy once tumors are surgically resected [4]. In the metastatic setting, there is an ongoing 
struggle to identify new and better treatment options for patients. Clearly, with a historical average 
overall survival of approximately 6 months, therapeutic options require improvement.  
Since the pivotal first-line clinical trial published in 1997, gemcitabine (2',2'-difluorodeoxycytidine) 
has been considered the mainstay therapy for advanced disease [3]. This trial randomized 126 patients 
to  gemcitabine  or  5FU  and  resulted  in  an  improvement  in  clinical  benefit,  a  composite  endpoint 
consisting of improvement in pain, performance status, and weight maintenance. Though the gain in 
median survival was statistically significant, the benefit was only 1.24 months. Hundreds of clinical 
trials investigating both standard cytotoxics and targeted agents have since been undertaken, almost all 
of which have failed. Proof of concept for the utility of biologics in advanced pancreas cancer occurred 
in 2007 when erlotinib, a small molecule inhibitor of the epidermal growth factor receptor (EGFR) 
pathway, in combination with gemcitabine improved survival for patients over gemcitabine alone [5]. 
The OS advantage with the addition of erlotinib, however, was less than 2 weeks and, as such, it is not 
widely  considered  clinically  relevant.  Other  targeted  agents,  including  but  not  limited  to,  small 
molecule and antibody directed inhibition of angiogenesis, antibody mediated inhibition of EGFR, and 
inhibiting mammalian target of rapamycin (mTOR) have been unsuccessful in phase II and phase III 
clinical  trials  [6–14].  Furthermore,  the  combination  of  more  than  one  biologic  has  not  been  
successful [15]. 
More recently, oxaliplatin-based cytotoxic therapy has emerged as a potential treatment option both 
in the first and second line setting for metastatic pancreas cancer. First line, the combination of 5FU, 
leucovorin, irinotecan, and oxaliplatin, known commonly as FOLFIRINOX, improves progression free 
survival and OS compared to single agent gemcitabine [16]. These results come with the caveat of 
significantly  increased  toxicity  including  grade  3  or  4  neutropenia,  febrile  neutropenia, 
thrombocytopenia, diarrhea, and sensory neuropathy. The study did not include patients older than 75. 
The  publication  clearly  states  FOLFIRINOX  should  only  be  administered  to  patients  with  good 
performance  status [16].  Second  line  oxaliplatin  based  treatment  in  combination  with  5FU  and 
leucovorin as part of a regimen, abbreviated as OFF, has also shown at least a 2 month OS benefit after 
gemcitabine  failure [17].  Again,  this  trial  was  limited  to  a  highly  selected  patient  population  with 
continued good performance status despite progressing on first line therapy. 
Due to the limited benefit of gemcitabine in an unselected patient population and the high level of 
potential toxicity with oxaliplatin based chemotherapy regimens, there is a desperate need to identify 
potential  biomarkers  in  the  treatment  of  pancreas  adenocarcinoma.  This  review  will  focus  on  the 
potential  current  relevant  biomarkers  which  may  be  predictive  or  prognostic  of  cytotoxic 
chemotherapies currently being used in metastatic pancreas cancer including biomarkers. 
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2. Gemcitabine Factors 
Although  FOLFIRINOX  offers  improved  PFS  and  OS  over  single  agent  gemcitabine,  it  is  not 
possible to offer this treatment to all patients due to its toxicities. As such, gemcitabine remains the 
clinical reference agent for the treatment of metastatic pancreas cancer as well as one of the only two 
options for treatment in the adjuvant setting. To date, despite leading experts stating their opinion that 
personalized medicine and chemotherapeutic options should take top priority in clinical trials, there 
have been no trials dedicated to the validation of a predictive or prognostic biomarker for gemcitabine 
utility.  Gemcitabine  is  a  pyrimidine  nucleoside  analog  with  activity  against  a  number  of  tumor 
types [18]. Gemcitabine exerts its cytotoxic effects inside the cell where kinases phosphorylate it to 
mono-, di-, and tri-phospate forms, the latter of the two being the active metabolites. Gemcitabine is 
self-potentiating with multiple mechanisms of action including DNA chain termination, induction of 
apoptosis, and DNA synthesis inhibition [19–21]. Once incorporated by deoxyribonucleic acid (DNA) 
and ribonucleic acid (RNA) gemcitabine is protected from base excision repair [19,22].  
As a hydrophilic compound, gemcitabine diffusion across the plasma membrane is difficult without 
the use of physiologic nucleoside transporter proteins. There are two known categories of nucleoside 
transporters: equilibrative (ENT) and concentrative (CNT) [23]. Both have data supporting their use as 
a biomarker to direct gemcitabine treatment. 
2.1. hENT1 
There are two human equilibrative nucleoside transporters (hENT), hENT1 and hENT2, which are 
found in most cell types and mediate concentration dependent gemcitabine cellular uptake [24]. These 
transmembrane  proteins  are  differentiated  functionally  by  their  sensitivity  to 
nitrobenzylmercaptopurine  ribonucleoside  (NBMPR)  with  hENT1  being  sensitive  while  hENT2  is 
not [25]. There is mounting evidence that hENT1 is a predictive and prognostic biomarker for the use 
of gemcitabine both in the adjuvant and metastatic setting. In 2004, hENT1 abundance in biopsies of 
patients  that  had  been  treated  with  gemcitabine  for  their  advanced  disease  was  retrospectively 
determined by immunohistochemistry [26]. The difference in overall survival between those patients 
that had uniform hENT1 on their tumors compared to those that did not have uniform hENT1 staining 
was 13 versus 4 months (p = 0.01). This initial study prompted further investigation into hENT1 as a 
biomarker to guide gemcitabine use.  
In  vitro,  higher  levels  of  hENT1  measured  by  quantitative  RT-PCR  increased  gemcitabine 
sensitivity [27]. Three common pancreas cancer cell lines had variable hENT1 expression and those 
with the most hENT1 were the most sensitive to gemcitabine cytotoxicity. Similar results have been 
seen in several in vivo retrospective assessments of the hENT1 in the setting of gemcitabine treatment. 
In both univariate and multivariate models, hENT1 expression via immunohistochemistry assessment 
on tissue microarrays was associated with improvements in OS and DFS in patients treated adjuvantly 
with gemcitabine [28]. In this study, 91 patients were treated on the gemcitabine arm with significant 
benefit seen in OS and DFS when low versus high, and high versus no hENT1 grouping were assessed. 
The same  findings were not seen  in the 5FU treated population. Further, evaluation hENT1 using 
standard immunohistochemistry methods of 45 patients who received gemcitabine treatment confirms Int. J. Mol. Sci. 2011, 12                       
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significantly longer DFS and OS with high hENT1 than with low hENT1. The median DFS and OS 
were 8.4 versus 46.8 months and 13.3 versus not yet reached at the time of publication for low versus 
high hENT1, respectfully [29]. Finally, 434 pancreas cancer patients have been evaluated for hENT1, 
243  of  which  received  gemcitabine  chemotherapy [30].  Overall  survival  was  associated  with 
gemcitabine and high hENT1 even when corrected for tumor grade, tumor size, lymph node status, and 
resection margins. There was no difference in OS between high and low hENT1 in those patients not 
exposed to gemcitabine. 
Transcriptional  analysis  of  hENT1  has  also  been  proven  to  be  a  prognostic  tool [31].  In  102 
evaluated  patients,  those  patients  with  high  hENT1  had  significantly  longer  OS  and  disease-free 
survival  as well as a  longer time to progression.  Multivariate analysis demonstrated hENT1 as an 
independent prognostic factor. 
2.2. hCNT3 
The other gemcitabine  membrane transporters are concentrative  in nature. Human concentrative 
nucleoside  transporter  1  (hCNT1),  2  (hCNT2),  and  3  (hCNT3)  use  the  sodium  gradient  to  move 
gemcitabine across the plasma membrane against the concentration gradient [24]. Ubiquitous, hCNT3 
is present in most tissues and is responsible for the majority of gemcitabine transport by the CNTs. 
There is not as much information in the medical literature regarding the use of hCNT3 as a biomarker 
in pancreas cancer. Maréchal  et al. evaluated hCNT3 alone and  in combination with hENT1 [29]. 
Alone,  high  versus  low  hCNT3,  as  determined  by  standard  immunohistochemistry  methods,  was 
associated with improvement in OS (not yet reached at the time of publication versus 21.6 months). 
Disease recurrence was increased (8.6 versus 23.5 months, p = 0.02) and three year survival was less 
(26.1% versus 54.6%, p = 0.028) in the hENT1 low versus high group. When hCNT3 is combined with 
hENT1,  the  three  year  survival  jumps  to  81.1%  suggesting  the  use  of  the  two  biomarkers  in 
combination may be more robust than using one alone.  
2.3. dCK 
Deoxycytidine kinase (dCK) is the enzyme responsible for the rate limiting step which converts 
administered gemcitabine to its active metabolites. An abundance of dCK, or an increase in its activity 
will increase the active forms of gemcitabine thereby potentially increasing gemcitabine efficacy [32]. 
Pre-clinically, a composite of hENT1, dCK, ribonucleoside-diphosphate reductase M1 (RRM1), and 
RRM2,  the  latter  two  also  being  involved  in  gemcitabine  transport  and  metabolism,  indicates 
gemcitabine sensitivity or resistance in eight pancreatic cell lines [33]. In vivo, high dCK mRNA levels 
in  70  patients  who  received  palliative  gemcitabine  treatment  correlated  with  significantly  longer 
DFS [34].  In  a  larger  patient  population  of  243  patients  treated  with  adjuvant  gemcitabine-based 
treatment after resection of their tumors, a significant interaction was seen with benefit in OS and dCK 
protein expression [30].  
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3. Tumor & Matrix Factors 
3.1. SPARC 
Secreted protein acidic and rich in cysteine (SPARC), also called osteonectin, is a protein located 
both on pancreas cancer tumor cells and fibroblasts within the peritumoral extracelllular matrix. It is 
involved  in  many  tumor  related  functions  including  adhesion,  remodeling,  angiogenesis,  and  cell 
migration and invasion [35–38]. SPARC has also been shown to have a role in growth rate modulation 
as demonstrated by SPARC knockout mice having increased rate of tumor growth than those mice 
with intact SPARC [39,40]. The abundance of SPARC on pancreas cancer cells and matrix fibroblast 
varies with tumors often losing SPARC expression due to epigenetic changes; this does not appear to 
be the case with fibroblasts [41].  
SPARC  is  emerging  as  a  possible  prognostic  biomarker  and  has  in  a  small  patient  population, 
demonstrated predictive capabilities in terms of being able to direct treatment decisions in pancreas 
adenocarcinoma. Multiple studies have demonstrated SPARC overexpression in a variety of cancers 
confers a poor prognosis [42–45]. In esophageal and gastric tumors, high SPARC is associated with 
lymph node metastases and worse clinical outcome [42,45]. In breast cancer, SPARC was found to be 
present  in  higher  quantities  than  normal  breast tissue  and  correlated  with  lymph  node  metastases, 
tumor grade, and 10-year survival [43]. In bladder cancer, there again was a connection between high 
SPARC  and  poor  prognosis  but  additionally,  gene  expression  of  SPARC  correlated  with  matrix 
metalloproteinase-2  (MMP-2)  expression [44].  MMP-2  is  a  matrix  protein  known  to  have  roles  in 
tissue breakdown, remodeling, and metastasis. This interaction may be a clue as to SPARC importance 
in patient clinical outcomes. 
In pancreas cancer, it is becoming clear that the location of SPARC overexpression is important. 
Infante et al. published data demonstrating it is the SPARC in pancreatic cancer stromal fibroblasts 
that confers a worse prognosis and not the SPARC on pancreatic tumor cells proper [46]. Patients 
whose tumors stoma was positive versus negative for SPARC had median OS of 15 versus 30months 
(p < 0.001); the same was not seen when comparing tumor cell SPARC. Early data also suggests a 
potential role to predict response to nab-paclitaxel, a drug currently under investigation in combination 
with gemcitabine for the treatment of advanced pancreas cancer [47]. This will be important if the 
ongoing phase III clinical trial portrays a survival advantage of the combination over single agent 
gemcitabine (NCT00398086). 
3.2. Prostate Stem Cell Antigen 
Prostate stem cell antigen (PSCA) is a cell surface protein present in about 70% of pancreas cancers 
with normal tissue expression being low [48,49]. PSCA copy number in the blood of patients with 
pancreas cancer compared to normal patients assessed with real-time quantitative polymerase chain 
reaction was significantly elevated [50]. Pre-clinical xenografts mouse models had inhibition of tumor 
growth  and  decrease  in  distant  metastases  when  exposed  to  an  anti-PSCA  mouse  monoclonal 
antibody [51].  Anti-PSCA  treatment  also  resulted  in  a  decrease  of  tumor  growth  initiation  in  a 
pancreatic cancer xenograft model using the Capan-1 cell  line [52]. AGS-1C4D4 is a fully  human 
IgG1κ  monoclonal  antibody  against  PSCA.  A  recent  clinical  trial  (NCT00902291)  reported  an Int. J. Mol. Sci. 2011, 12                       
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improved  6  month  survival  rate  in  patients  with  PSCA  positive  tumors  in  patients  receiving  the 
combination  of  AGS-1C4D4  +  gemcitabine  versus  gemcitabine  alone [53].  Together,  these  data 
suggest PSCA is a negative prognostic feature for pancreas cancer and a possible predictor of anti-
PSCA therapy. 
4. Other Factors 
There are a few other potential pancreatic cancer biomarkers that may have clinical impact in the 
future though none are as robust as those discussed above. Tissue microarrays have been shown to 
have potential utility to identify possible patterns associated with pancreas cancer, possibly leading to 
the discovery of a gene or protein that might be a predictive or prognostic tool [54–57]. Other possible 
markers  in  early  development  include  the  following:  in  vitro,  activated  leukocyte  cell  adhesion 
molecule (ALCAM, CD166) as a marker of cell adhesion and chemoresistance [58]; pancreatic stellate 
cells (PSCs), isolated according to CD10 surface expression, are associated with lymph node status, 
increased  invasiveness,  and decreased survival [59];  lack of or weak nuclear staining of the  basic 
helix-loop-helix  domain  containing  class-B2  transcriptional  factor  BHLHB2  which  is  induced  by 
hypoxia, a common finding in pancreas cancer, confers a median survival of 13 months compared to 
27  months  with  strong  staining  (p  =  0.03)  and  is  touted  as  an  independent  prognostic  factor  for 
survival [60];  and  finally,  Dkk-3  (a  member  of  the  Wnt  signaling  cascade  and  a  possible  tumor 
suppressor) overexpression correlates with tumor growth inhibition after gemcitabine or 5FU exposure 
and as such may be a predictor of chemotherapy efficacy [61]. 
The targeting of angiogenesis has not been a successful endeavor for the treatment of pancreas 
cancer. Noted above, clinical trials using either monoclonal antibodies or small molecule inhibitors of 
the vascular endothelial growth factor (VEGF) receptor (VEGFR) pathway have failed to demonstrate 
benefit [6–10]. To the contrary, pre-clinical data supports the effectiveness of inhibiting the VEGF 
family  with  a  halting  of  tumor  growth  likely  mediated  by  decreasing  neovascularization  and 
lymphangiogenesis  while  increasing  meaningful  delivery  of  cytotoxic  drugs [62,63].  A  possible 
prognostic test, higher pre-treatment serum VEGF/soluble VEGFR-1 ratio is associated with worse 
survival in patients with pancreas cancer [64]. In addition, and not discussed in this review, there exists 
a whole body of literature supporting the use of these agents and possible mechanisms of resistance to 
them in pancreas cancer. Unfortunately, positive findings linking antiangiogenic agents and pancreas 
cancer are meaningless if the drugs targeting this pathway are ineffective in the clinical setting.  
5. Conclusions  
In  a  consensus  report  from  the  National  Cancer  Institute  clinical  trials  planning  committee  on 
pancreas cancer treatment, experts put a focus on the discovery, development, and validation of one or 
more biomarkers for this deadly disease [65]. After all, wouldn’t it be ideal to explain to a patient that, 
based on a biomarker in their tumor, they should be treated with drug A and not drug B, or vice versa. 
Similarly,  if  a  metastatic  patient  with  performance  status  that  does  not  allow  for  delivery  of 
FOLFIRINOX  was  in  clinic,  would  it  not  be  important  to  know  that  a  biomarker  can  determine 
whether they will benefit from gemcitabine, as if not, their best option may be to control symptoms in 
the last few months of their lives without chemotherapy. To date, despite leading experts stating their Int. J. Mol. Sci. 2011, 12                       
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opinion that personalized medicine and chemotherapeutic options should take priority in clinical trials, 
there  have  been  no  trials  dedicated  to  the  validation  of  a  predictive  or  prognostic  biomarker  for 
gemcitabine, 5FU, or oxaliplatin-based chemotherapy utility in pancreas cancer. Perhaps the reasons 
include the sense that we are still not at the point in pancreas cancer to have a robust enough biomarker 
data to determine efficacy of one or more of our active drugs or perhaps it is because clinical trials are 
still  driven  by  financial  considerations  and  profit  margins  for  drug  company  sponsors.  One  could 
challenge that line of thinking as we have not made much in the way of progress to date by simply 
guessing and testing a new drug or a drug combination. 
At this time, hENT1,  hCNT3, SPARC and PSCA are the  most clinically  advanced biomarkers. 
They have all been investigated retrospectively and are shown to have some utility associated with 
gemcitabine,  nab-paclitaxel,  or  AGS-1C4D4  treatment.  Unfortunately  there  is  little  information 
regarding biomarkers for FOLFIRINOX at the current time. One could argue that, though this is now 
considered the reference combination for patients, in reality, its generalized clinical use is difficult 
without modifications to the regimen in one form or another. 
The bottom line is that we need better treatments for pancreas cancer and biomarkers should be 
used both retrospectively and a priori in future clinical trials. One method of achieving this is to select 
a patient population via one or more biomarkers to guide therapy decisions. Our group has recently 
received grant funding from the Alberta Health Innovates Health Solutions and the Alberta Cancer 
Foundation where we will integrate a priori biomarker testing in clinical trials for both the adjuvant 
and metastatic pancreas cancer patient population. To our knowledge this is a relatively novel course 
in pancreas cancer clinical trials and one that should be actively pursued. The goal is to personalize the 
treatment for our pancreas cancer patients for better outcomes and more tolerable toxicities. 
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